Chris Rallis
Fortune : 626 355 $ au 31/05/2026
Fortune : 626 355 $ au 31/05/2026
Chris A. Rallis is currently an Independent Director at Fennec Pharmaceuticals, Inc. since 2011 and a Director at Salisbury School, Inc. Formerly, Mr. Rallis was President & Chief Executive Officer at ImmunoBiosciences, Inc. from 2006 to 2007, Independent Director at Tenax Therapeutics, Inc. from 2011 to 2021, and President, Chief Operating Officer & Director at Triangle Pharmaceuticals, Inc. from 1995 to 2003.
Other former roles include Director positions at Incara Pharmaceuticals Corp., Soligenix, Inc., EMD Millipore Corp., Lee's Pharmaceutical Holdings Ltd., Naicons Srl, Lung Cancer Initiative, and Independent Director at Aeolus Pharmaceuticals, Inc. Also held the position of VP-Strategic Planning & Business Development at Burroughs Wellcome.
Education includes graduate studies at Duke University and undergraduate studies at Harvard College.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 10/06/2026 | 63 077 ( 0,18 % ) | 626 355 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| FENNEC PHARMACEUTICALS INC. | Directeur/Membre du Conseil | 25/08/2011 |
Salisbury School, Inc. | Directeur/Membre du Conseil | - |
| Sociétés | Poste | Fin |
|---|---|---|
| TENAX THERAPEUTICS, INC. | Directeur/Membre du Conseil | 10/06/2021 |
ImmunoBiosciences, Inc.
ImmunoBiosciences, Inc. Packaged SoftwareTechnology Services Develops a vaccine platform technology solution to create vaccines to combat diseases | Directeur Général | 01/06/2007 |
Incara Pharmaceuticals Corp.
Incara Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of cardiovascular and pulmonary diseases | Directeur/Membre du Conseil | 09/08/2004 |
Triangle Pharmaceuticals, Inc.
Triangle Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Develops antiviral drug candidates | President | 01/01/2003 |
Lung Cancer Initiative
Lung Cancer Initiative Miscellaneous Commercial ServicesCommercial Services Lung Cancer Initiative is a nonprofit organization dedicated to improving the lives of those affected by lung cancer through research funding, education, patient support, and community engagement. The private company is located in the US. The organization invests in lung cancer research, focusing on early-career investigators and innovative projects to advance diagnosis, treatment, and survivorship. It offers patient and caregiver support programs, including financial assistance, peer-to-peer support, survivor engagement events, and access to pharmaceutical assistance programs. Educational resources and workshops are provided to help patients, caregivers, and healthcare professionals understand lung cancer diagnosis, treatment options, and survivorship care. The organization partners with professional medical societies to enhance lung cancer care and education. Lung Cancer Initiative connects patients, survivors, and their loved ones with the medical and research community to advance survivorship and provide support through research, education, and access to programs. | Directeur/Membre du Conseil | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 15 |
|---|---|
Soligenix, Inc.
Soligenix, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and commercializes biodefense vaccines and oral therapeutic products | Health Technology |
EMD Millipore Corp.
EMD Millipore Corp. Miscellaneous Commercial ServicesCommercial Services Engages in research, development and production of biotechnology & pharmaceutical drug therapies | Commercial Services |
Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes pharmaceutical therapeutic products | Health Technology |
Triangle Pharmaceuticals, Inc.
Triangle Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Develops antiviral drug candidates | Commercial Services |
Incara Pharmaceuticals Corp.
Incara Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of cardiovascular and pulmonary diseases | Health Technology |
Fennec Pharmaceuticals, Inc.
Fennec Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops and commercializes therapeutic products which dedicated to improving the lives of children with cancer who experience hearing loss | Health Technology |
Lee's Pharmaceutical Holdings Ltd.
Lee's Pharmaceutical Holdings Ltd. Pharmaceuticals: MajorHealth Technology Engages in the drug development, clinical development, regulatory, manufacturing, selling and marketing of pharmaceutical products | Health Technology |
ImmunoBiosciences, Inc.
ImmunoBiosciences, Inc. Packaged SoftwareTechnology Services Develops a vaccine platform technology solution to create vaccines to combat diseases | Technology Services |
Duke University
Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aeolus Pharmaceuticals, Inc.
Aeolus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical drugs | Health Technology |
Burroughs Wellcome | |
Salisbury School, Inc. | |
Harvard College
Harvard College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Naicons Srl
Naicons Srl Packaged SoftwareTechnology Services Develops game-changing drug discovery platform | Technology Services |
Lung Cancer Initiative
Lung Cancer Initiative Miscellaneous Commercial ServicesCommercial Services Lung Cancer Initiative is a nonprofit organization dedicated to improving the lives of those affected by lung cancer through research funding, education, patient support, and community engagement. The private company is located in the US. The organization invests in lung cancer research, focusing on early-career investigators and innovative projects to advance diagnosis, treatment, and survivorship. It offers patient and caregiver support programs, including financial assistance, peer-to-peer support, survivor engagement events, and access to pharmaceutical assistance programs. Educational resources and workshops are provided to help patients, caregivers, and healthcare professionals understand lung cancer diagnosis, treatment options, and survivorship care. The organization partners with professional medical societies to enhance lung cancer care and education. Lung Cancer Initiative connects patients, survivors, and their loved ones with the medical and research community to advance survivorship and provide support through research, education, and access to programs. | Commercial Services |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national